"Malaysia Pharmaceuticals & Healthcare Report Q3 2012" Now Available at Fast Market Research
BMI View: The Malaysian pharmaceutical market is relatively underdeveloped by international standards, with low per capita sales (US$63 in 2011) constrained by the limited government role in terms of healthcare financing in general. Through to 2016, the Malaysian drug market, valued at around MYR5.55bn (US$1.81bn) in 2011, is expected to post a compound annual growth rate (CAGR) of 9.4% in local currency terms, driven primarily by the expansion and modernisation of healthcare facilities and the increase in the number of...
View full press release